Article révisé par les pairs
Résumé : Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients < 65 vs. ≥65 years, and for those with lymphocyte counts ≥ 1000/µL vs. <1000/µL or lactate dehydrogenase ≤ ULN vs. >ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL.

Documents en relation

DI-fusion

  • Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
    par Schuster, Michael , Zijlstra, Josée J.M. , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Neste, Eric Van Den , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Follows, George , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel , Maerevoet, Marie
    Publication 2022
  • Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
    par Maerevoet, Marie , Zijlstra, Josée J.M. , Follows, George , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Van Den Neste, Eric , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jaeger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel
    Publication 2021-12
  • Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
    par Casasnovas, René Olivier , Follows, George , Zijlstra, Josée J.M. , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Choquet, Sylvain , Neste, Eric Van Den , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , La Cruz, Fátima De , Kuruvilla, John , Hamad, Nada , Jaeger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Chamoun, Kamal , Shah, Jatin , Canales, Miguel , Maerevoet, Marie , Shacham, Sharon , Kauffman, Michael , Goy, Andre
    Publication 2021
  • Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
    par Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Daniele, Patrick , Tomaras, Dimitrios , Tremblay, Gabriel , Casasnovas, René Olivier , Maerevoet, Marie , Zijlstra, Josée J.M. , Follows, George , P Vermaat, Joost J.S. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Den Neste, Eric Van , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , La Cruz, Fátima De , Kuruvilla, John , Hamad, Nada , Bouabdallah, Reda , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vasilakopoulos, Theodoros T.P. , Samal, Priyanka , Nagy, Agnes , Ku, Matthew , Canales Albendea, Miguel Ángel
    Publication 2021-04
  • Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
    par Kalakonda, Nagesh , Maerevoet, Marie , Cavallo, Federica , Follows, George , Goy, Andre , Vermaat, Joost J.S.P. , Casasnovas, Olivier , Hamad, Nada , Zijlstra, Josée J.M. , Bakhshi, Sameer , Bouabdallah, Reda , Choquet, Sylvain , Gurion, Ronit , Hill, Brian , Jaeger, Ulrich , Sancho, Juan Manuel , Schuster, Michael , Thieblemont, Catherine , De la Cruz, Fátima , Egyed, Miklos , Mishra, Sourav , Offner, Fritz , Vassilakopoulos, Theodoros , Warzocha, Krzysztof , McCarthy, Daniel , Ma, Xiwen , Corona, Kelly , Saint-Martin, Jean-Richard , Chang, Hua , Landesman, Yosef , Joshi, Anita , Wang, Hongwei , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Van Den Neste, Eric , Canales, Miguel Ángel M.A.
    Publication 2020-07